LBA77 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): A randomized phase III trial sponsored by the FFCD

Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, E. Samalin-Scalzi, Karine Le Malicot, Simon Pernot, Pascal Artru, V. Ly Lebrun, Kaïs Aldabbagh, F. Khemissa Akouz, H. Castanie, Margot Laly, Damien Botsen, Marie Müller, Gaël S. Roth, Thierry Lecomte, Jean–Marc Phelip, Côme Lepage, Christophe Louvet